title: The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children.
abstract: OBJECTIVE
  To study Hodgkin lymphoma (HL) microenvironment in a Swedish paediatric population and its relation to clinical parameters.
  
  
  METHODS
  Tumour tissue from classical HL (cHL) (n = 87) and nodular lymphocyte predominant HL (NLPHL) (n = 11) was investigated for Epstein-Barr Virus (EBV) and analysed for eosinophils, mast cells and macrophages.
  
  
  RESULTS
  In cHL, EBV positivity was more common in low age (P < 0.001) and in mixed cellularity (MC) (P < 0.001). Higher mast cell infiltration was seen in stage III-IV (P < 0.001), and with presence of B-symptoms (P = 0.01). Cases with high mast cell counts displayed higher erythrocyte sedimentation rate (ESR), lower haemoglobin and albumin levels. Higher macrophage infiltration was seen in stage III-IV (P = 0.02) and there was elevated ESR and neutrophil count. All NLPHL cases were EBV negative, had lower rates of inflammatory cells and lower degree of inflammatory reaction in laboratory parameters. There was no difference in survival estimates with regard to infiltration of inflammatory cells.
  
  
  CONCLUSIONS
  Higher levels of mast cells and macrophages in cHL tumours reflected the clinical presentation in laboratory parameters, B-symptoms and more advanced stages. NLPHL differs from cHL in numbers of inflammatory cells in the tumour, and in laboratory parameters.
authors.affiliation: Department of Women's and Children's Health, Paediatric Oncology, Uppsala University, Uppsala, Sweden. annika.englund@kbh.uu.se.
authors.forename: Annika
authors.initials: A
authors.lastname: Englund
authors.affiliation: Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.
authors.forename: Daniel
authors.initials: D
authors.lastname: Molin
authors.affiliation: Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.
authors.forename: Gunilla
authors.initials: G
authors.lastname: Enblad
authors.affiliation: Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Jonas
authors.initials: J
authors.lastname: Karlén
authors.affiliation: Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Glimelius
authors.affiliation: Department of Women's and Children's Health, Paediatric Oncology, Uppsala University, Uppsala, Sweden.
authors.forename: Gustaf
authors.initials: G
authors.lastname: Ljungman
authors.affiliation: Department of Immunology, Genetics and Pathology, Unit of Pathology, Uppsala University, Uppsala, Sweden.
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Amini
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004804:Eosinophils / Q000473:pathology*; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008214:Lymphocytes / Q000473:pathology*; D008264:Macrophages / Q000473:pathology*; D008297:Male; D008407:Mast Cells / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D013548:Sweden; D059016:Tumor Microenvironment
keywords: Hodgkin; Microenvironment; eosinophils; macrophages; mast cells; paediatric